Available:*
Library | Item Barcode | Call Number | Material Type | Item Category 1 | Status |
---|---|---|---|---|---|
Searching... | 30000010290561 | QP552.G16 G676 2011 | Open Access Book | Book | Searching... |
On Order
Summary
Summary
Provides a comprehensive overview of recent discoveries and current understandings of G protein-coupled receptors (GPCRs). Recent advances include the first mammalian non-rhodopsin GPCR structures and reconstitution of purified GPCRs into membrane discs for defined studies, novel signaling features including oligomerization, and advances in understanding the complex ligand pharmacology and physiology of GPCRs, in new assay technologies and drug targeting. The authors take time to detail the importance of the pathophysiological function and drug targeting of GPCRs, specifically β-adrenoceptors in cardiovascular and respiratory diseases, metabotropic glutamate receptors in CNS disorders, S1P receptors in the immune system, and Wnt/Frizzled receptors in osteoporosis. This book will be invaluable to researchers and graduate students in academia and industry who are interested in the GPCR field.
Author Notes
Dr. Sandra Siehler is a Research Investigator at the Novartis Institutes for BioMedical Research in Basel, Switzerland. Dr. Siehler is a member of the American Society for Pharmacology and Experimental Therapeutics and the British Pharmacological Society.
Dr. Graeme Milligan is Professor of Molecular Pharmacology at the University of Glasgow. He is actively involved in numerous associations, such as the Biochemical Society and the British Pharmacology Society. Dr. Milligan was awarded the Ariens Award for Pharmacology from the Dutch Pharmacological Society in 2006.
Table of Contents
List of Figures | p. vii |
List of Tables | p. xi |
List of Contributors | p. xiii |
Introduction | p. 1 |
Part I Advances in GPCR Protein Research | |
1 The evolution of the repertoire and structure of G protein-coupled receptors | p. 5 |
2 Functional studies of isolated GPCR-G protein complexes in the membrane bilayer of lipoprotein particles | p. 32 |
Part II Oligomerization of GPCRs | |
3 GPCR-G protein fusions: Use in functional dimerization analysis | p. 53 |
4 Time-resolved FRET approaches to study GPCR complexes | p. 67 |
5 Signaling of dopamine receptor homo-and heterooligomers | p. 90 |
6 Functional consequences of chemokine receptor dimerization | p. 111 |
Part III GPCR Signaling Features | |
7 G protein functions identified using genetic mouse models | p. 125 |
8 Kinetics of GPCR, G protein, and effector activation | p. 145 |
9 RGS-RhoGEFs and other RGS multidomain proteins as effector molecules in GPCR-dependent and GPCR-independent cell signaling | p. 159 |
10 Adenylyl cyclase isoform-specific signaling of GPCRs | p. 189 |
11 G protein-independent and ß arrestin-dependent GPCR signaling | p. 217 |
12 Assays to read GPCR modulation and signaling | p. 231 |
Part IV Ligand Pharmacology of GPCRS | |
13 Assessing allosteric ligand-receptor interactions | p. 247 |
14 7TM receptor functional selectivity | p. 270 |
Part V Physiological Functions and Drug Targeting of GPCRS | |
15 ß-Adrenoceptors in cardiovascular and respiratory diseases | p. 287 |
16 Role of metabotropic glutamate receptors in CNS disorders | p. 321 |
17 S1P receptor agonists, a novel generation of immunosuppressants | p. 380 |
18 Wnt/Frizzled receptor signaling in osteoporosis | p. 398 |
Index | p. 415 |